Ireland - English - HPRA (Health Products Regulatory Authority)

glaxosmithkline consumer healthcare (ireland) limited - calcium lactogluconate, calcium carbonate - tablets - 1000 milligram - calcium

Ireland - English - HPRA (Health Products Regulatory Authority)

glaxosmithkline consumer healthcare (ireland) limited - cholecalciferol concentrate ; calcium carbonate - chewable tablet - 500 mg/1000 international unit(s) - calcium, combinations with vitamin d and/or other drugs

Malta - English - Medicines Authority

glaxosmithkline consumer healthcare (ireland) limited 12, riverwalk, citywest business campus, dublin 24, ireland - ibuprofen, pseudoephedrine hydrochloride - coated tablet - ibuprofen 200 mg pseudoephedrine hydrochloride 30 mg - antiinflammatory and antirheumatic products

Ireland - English - HPRA (Health Products Regulatory Authority)

glaxosmithkline consumer healthcare (ireland) limited - amoxicillin trihydrate clavulanate potassium - film coated tablet - 875/125 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

glaxosmithkline consumer healthcare (ireland) limited - nicotine resinate - lozenges - 4 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

glaxosmithkline consumer healthcare (ireland) limited - nicotine resinate - lozenges - 1.5 milligram

Malta - English - Medicines Authority

glaxosmithkline consumer health-care uk trading limited - aciclovir; hydrocortisone - cream - aciclovir 50 mg; hydrocortisone 10 mg - antibiotics and chemotherapeutics for dermatological use

Malta - English - Medicines Authority

glaxosmithkline consumer health-care uk trading limited - fluticasone propionate - nasal spray, suspension - fluticasone propionate 0.5 mg - nasal preparations

European Union - English - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - split influenza virus, inactivated, containing antigen: a/vietnam/1194/2004 (h5n1) like strain used (nibrg-14) - influenza, human; immunization; disease outbreaks - vaccines - active immunisation against h5n1 subtype of influenza a virus.this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of vaccine prepared from a/vietnam/1194/2004 nibrg-14 (h5n1) (see section 5.1).prepandemic influenza vaccine (h5n1) (split virion, inactivated, adjuvanted) glaxosmithkline biologicals 3.75 µg should be used in accordance with official guidance.

European Union - English - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - split influenza virus, inactivated, containing antigen: a/vietnam/1194/2004 (h5n1) like strain used (nibrg-14) - influenza, human - vaccines - prophylaxis of influenza in an officially declared pandemic situation. pandemic influenza vaccine should be used in accordance with official guidance.